HOME
-
Libentech
-
Company profile
VISION
HISTORY
2024
01.
U.S. patent registration for LVP-K-PTEN, a colorectal cancer treatment
04.
Be awarded the 2024 BioTech Korea IR/Partnership Support Program
Be awarded the 2024 BioGlobal Startup and Business Expansion Support Program (TP)
06.
Successfully approved for the TIPS Program
(TIPS Project S3271268)
12.
Be awarded the 24-8th Scale-up TIPS Program
(Startup R&D, Ministry of SMEs and Startups)
2023
02.
Joint research agreement with
the National Cancer Center
03.
Business cooperation agreement for the commercialization of a virus kit with GW Biotech
09.
Technology consultation meeting with Amgen
10.
U.S. patent registration for cancer cell-specific oncolytic virus production technology
2022
05.
Development of a colorectal cancer virus therapy as part of the SME Technology Innovation Development Program
(Korea Technology and Information Promotion Agency for SMEs)
10.
Patent registration in the U.S. and South Korea for LVP-K-PTEN as a brain cancer treatment
2021
04.
Be awarded the Big3 Startup Program
(Korea Startup Promotion Agency) for the development of a COVID-19 variant vaccine
09.
U.S. patent registration for a COVID-19 vaccine
using the LVP-K vector system
11.
Technology consultation meeting
with a pharmaceutical company
12.
Patent registration in South Korea for a COVID-19 vaccine and brain tumor treatment
2020
02.
Be awarded the TIPS Program
(Ministry of SMEs and Startups)
06.
Be awarded a Big3 company
(Ministry of SMEs and Startups)
07.
Establishment of an affiliated corporate research institute
10.
Conclude an MOU for technology collaboration
with Daewoong Pharmaceutical Co. LTD
2019
07.
Company foundation
09.
Development of an oncolytic virus based on the
LVP-K virus vector platform
11.
Be certified as a venture company